Evaluation of patients with acute pancreatitis associated with SARS-CoV-2 (COVID-19); The importance of lipase/lymphocyte ratio in predicting mortality

Abstract

BACKGROUND: SARS-CoV-2 is the cause of a pandemic with high mortality. In the present study, the effects of the lipase/lymphocyte ratio on mortality were investigated in cases diagnosed with Covid-19 and acute pancreatitis. METHODS: A total of 21 patients who were diagnosed with Covid-19 and acute pancreatitis, 34 patients who were not diagnosed with COVID-19 but diagnosed with acute pancreatitis, and 55 healthy control groups were divided into 3 groups and included in the study retrospectively. The patients who had positive RT-PCR (real-time polymerized chain reaction) test results were included in the study. Complete blood count and biochemical values of the patients were compared with those of the control group. RESULTS: When the data of the cases diagnosed with COVID-19 and acute pancreatitis were examined retrospectively, the amylase, lipase, lipase/lymphocyte ratio, and D-dimer levels were found to be signifi cantly higher than in the control group (p < 0.01). In the ROC analysis, the amylase, lipase, and lipase/lymphocyte ratio had a high AUC (area under the curve) value (0.993 / 0.949 / 0.978, respectively). CONCLUSION: The lipase/lymphocyte ratio can be used in cases diagnosed with Covid-19 and acute pancreatitis to predict mortality (Tab.

COVID-19 Infection Deteriorates the Clinical Condition and Outcomes of Acute Pancreatitis: A Meta-Analysis

“…e pooled results showed that the incidence of ALI/ARDS in the COVID-19 positive group was significantly higher than that of the COVID-19 negative group (OR � 3.03; 95% CI: 2.09 to 4.39, P < 0.00001; P � 0.20 for heterogeneity) (Table 2). However, the incidence of renal failure [14,16,17] and multiple organ dysfunction syndrome (MODS) [14,16] in the COVID-19 positive group was comparable to those of the COVID-19 negative group (Table 2).…”

“…Furthermore, specified organ failures were analyzed. Cardiovascular failures were reported by two studies, involving 370 patients [16,17]. e incidence of cardiovascular failure in the COVID-19 positive group was significantly higher than that of the COVID-19 negative group (OR � 2.92; 95% CI: 1.66 to 5.14, P � 0.0002; P � 0.58 for heterogeneity) (Table 2).…”

“…Full texts of the remaining 17 studies were carefully read according to the inclusion and exclusion criteria. Finally, seven studies were included in the qualitative synthesis [11][12][13][14][15][16][17].…”

“…e incidence of cardiovascular failure in the COVID-19 positive group was significantly higher than that of the COVID-19 negative group (OR � 2.92; 95% CI: 1.66 to 5.14, P � 0.0002; P � 0.58 for heterogeneity) (Table 2). Moreover, acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) was reported by four studies, with 260 patients in the COVID-19 positive group and 1712 patients in the COVID-19 negative group [11,14,16,17]. e pooled results showed that the incidence of ALI/ARDS in the COVID-19 positive group was significantly higher than that of the COVID-19 negative group (OR � 3.03; 95% CI: 2.09 to 4.39, P < 0.00001; P � 0.20 for heterogeneity) (Table 2).…”

“…Length of hospital stay was reported by four studies, with 232 patients in the COVID-19 positive group and 1789 patients in the COVID-19 negative group [11,12,14,16] e length of hospital stay in the COVID-19 positive group was significantly longer than that in the COVID-19 negative group (MD � 4.53; 95% CI: 0.96 to 8.10, P � 0.01; P � 0.02 to heterogeneity). As for the mortality comparison between the two groups, data on mortality were reported by seven studies, with 406 patients in the COVID-19 positive group and 2112 patients in the COVID-19 negative group [11][12][13][14][15][16][17]. e mortality rate in the COVID-19 positive group was significantly higher than that of the negative group (OR � 3.70; 95% CI: 2.60 to 5.25, P < 0.00001; P � 0.12 for heterogeneity) (Table 2).…”